USPTO serial 79165660
BAXALTA
Reviewed by CopyMark Law Group
Reg. 4961987Status 707Renewal
- Filing date
- Status date
- Registration date
- May 24, 2016
- Examiner
- CARLSON, KRISTIN
- Law office
- —
What this means
This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.
Need help with BAXALTA?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $748*
Plus Government fees of $1,700
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
US
Bannockburn, IL
Bannockburn, IL
Bannockburn, IL
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
A. Tally Eitan
A. Tally Eitan Gornitzky & Co6480 Calverton Drive, Unit 202C/o Edna EisemannFrederick, MD 20874Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations, substances and products for the treatment of blood diseases and disorders, immuno deficiency disorders, cancer; pharmaceuticals for the treatment of blood diseases and disorders, immuno deficiency disorders, cancer; pharmaceutical preparations, namely, proteinase inhibitors in the nature of alpha-1 proteinase inhibitors; pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders, all containing immune globulin infusion (human) and recombinant human hyaluronidase; reconstitution assembly sold containing vials prefilled with pharmaceutical preparations for the treatment of blood diseases and disorders; normal serum albumin (human) solution for intravenous administration; immunoglobulin for parenteral, intramuscular and intravenous administration to humans; antihemophilic factor for intravenous administration in humans; antihemophilic factor recombinant; pharmaceutical preparations, namely, chemotherapeutic agents | ACTIVE | — |
| 009 | [Computer software for use in the inputting of patient information for transmission to health care professionals; computer software for use in calculating and tailoring the optimal dosage for patients; computer application software for recording and analyzing patient information; computer application software, namely, software for tracking and managing patients' medication and wellness; computer software for tracking and managing pharmaceutical infusions and physical conditions of patients with bleeding disorders; computer software program for mobile phones, tablets, hand held devices and computers for tracking patient information and providing educational information in the field of hemophilia treatment options, designed for patients and health care professionals; downloadable electronic publications, namely, newsletters, articles, brochures, booklets, white papers and presentations in the field of pharmaceuticals, health care, health insurance, medical information, bleeding conditions, hemophilia, hematology, immunology, oncology and patient care] | SECTION 71 - CANCELLED | — |
| 010 | Medical devices, namely, devices for reconstituting dried pharmaceuticals; medical apparatus and instruments, namely, medical infusion set for subcutaneous delivery of pharmaceuticals; medical apparatus for the preparation and parental infusion of pharmaceutical preparations | ACTIVE | — |
| 016 | [Printed publications for teaching, namely, brochures, booklets, training manuals and teaching materials, newsletters and white papers in the fields of pharmaceuticals, health care, health insurance, medical information, bleeding conditions, hemophilia, hematology, immunology, oncology and patient care; printed publications, namely, brochures, booklets, training manuals and teaching materials, newsletters and white papers in the fields of pharmaceuticals, health care, health insurance, medical information, bleeding conditions, hemophilia, hematology, immunology, oncology and patient care; publications, namely, printed instructional and educational guides featuring information about bleeding conditions] | SECTION 71 - CANCELLED | — |
| 038 | [Provision of access to computer databases containing medical information related to hematological, immunological and oncological diseases, disorders and treatment] | SECTION 71 - CANCELLED | — |
| 041 | [Education and training services, namely, providing classes, seminars, conferences, lectures and workshops in the fields of pharmaceuticals, health care, health insurance, medical information, bleeding disorders or conditions, hemophilia, hematology, immunology, oncology and patient care; education services, namely, providing non-downloadable electronic publications in the nature of newsletters and white papers in the field of hemophilia; provision of information for training and teaching relating to pharmaceuticals, health care, health insurance, medical information, bleeding disorders or conditions, hemophilia, hematology, immunology, oncology and patient care; provision of non-downloadable electronic publications, namely, newsletters, articles, brochures and booklets in the field of pharmaceuticals, health care, health insurance, medical information, bleeding disorders or conditions, hemophilia, hematology, immunology, oncology and patient care] | SECTION 71 - CANCELLED | — |
| 044 | [Medical services and health care; health care services, namely, providing care for human health; medical services, namely, human blood component collection services; medical services, namely, blood purification; medical services, namely, providing medical information in the field of oncology, immunology and hematology via a website; providing an online database for identifying the optimal dosage of medications for patients; medical services, namely, providing free trial prescription service programs for pharmaceutical preparations for the treatment of blood disorders] | SECTION 71 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Baxter International Inc.
- Other trademarks owned by Baxalta Incorporated
- Other trademarks owned by Baxalta Incorporated
- Other trademarks owned by Baxalta Incorporated
- Other trademarks in Class 005
- Other trademarks in Class 009
- Other trademarks in Class 010
- Other trademarks in Class 016
- Other trademarks in Class 038
- Other trademarks in Class 041
- Other trademarks in Class 044
- Similar marks named BAXALTA
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| May 24, 2025 | REM4 | COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED | — |
| Feb 28, 2025 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Dec 12, 2024 | RNWL | INTERNATIONAL REGISTRATION RENEWED | — |
| Oct 15, 2023 | INNP | PARTIAL INVALIDATION PROCESSED BY THE IB | — |
| Aug 30, 2023 | INPS | PARTIAL INVALIDATION OF REG EXT PROTECTION SENT TO IB | — |
| Aug 30, 2023 | INPC | INVALIDATION PROCESSED | — |
| Aug 1, 2023 | INPR | PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED | — |
| Dec 1, 2022 | NA71 | NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED | — |
| Dec 1, 2022 | 71.P | REGISTERED - PARTIAL SEC 71 ACCEPTED | — |
| Nov 7, 2022 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Oct 22, 2022 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Oct 21, 2022 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| May 23, 2022 | ES71 | TEAS SECTION 71 RECEIVED | — |
| May 24, 2021 | REM3 | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED | — |
| Apr 8, 2017 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Sep 15, 2016 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Sep 15, 2016 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Aug 25, 2016 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Aug 25, 2016 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Aug 24, 2016 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| May 24, 2016 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Mar 8, 2016 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Mar 8, 2016 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Mar 4, 2016 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Feb 17, 2016 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Feb 17, 2016 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Feb 17, 2016 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Feb 3, 2016 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Jan 27, 2016 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jan 15, 2016 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jan 14, 2016 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jan 14, 2016 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| Jan 11, 2016 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Jan 11, 2016 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Jan 11, 2016 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Dec 19, 2015 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Dec 19, 2015 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Dec 19, 2015 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Dec 18, 2015 | ALIE | ASSIGNED TO LIE | — |
| Dec 4, 2015 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Nov 19, 2015 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Nov 19, 2015 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Oct 1, 2015 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Jul 31, 2015 | CHLD | CHANGE OF OWNER RECEIVED FROM IB | — |
| Jun 27, 2015 | RFNT | REFUSAL PROCESSED BY IB | — |
| Jun 9, 2015 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Jun 9, 2015 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Jun 6, 2015 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Jun 5, 2015 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 5, 2015 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Jun 2, 2015 | DOCK | ASSIGNED TO EXAMINER | — |
| Jun 1, 2015 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| May 30, 2015 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |